Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1923 1
1948 1
1972 2
1973 1
1974 1
1975 3
1976 1
1977 5
1978 2
1979 1
1980 1
1981 2
1982 8
1983 6
1984 8
1985 7
1986 8
1987 8
1988 10
1989 15
1990 19
1991 12
1992 11
1993 11
1994 14
1995 20
1996 19
1997 26
1998 21
1999 26
2000 28
2001 28
2002 34
2003 41
2004 40
2005 42
2006 45
2007 62
2008 64
2009 73
2010 64
2011 64
2012 58
2013 80
2014 67
2015 62
2016 85
2017 97
2018 97
2019 90
2020 105
2021 108
2022 100
2023 108
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

1,721 results

Results by year

Filters applied: . Clear all
Page 1
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.
Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Duran EK, et al. J Am Coll Cardiol. 2020 May 5;75(17):2122-2135. doi: 10.1016/j.jacc.2020.02.059. J Am Coll Cardiol. 2020. PMID: 32354380 Free PMC article. Clinical Trial.
METHODS: In a prospective case-cohort study within the Women's Health Study, TRL-C and sdLDL-C (mg/dl) were directly measured in baseline blood specimens of case subjects (n = 480) and the reference subcohort (n = 496). ...These findings signal that the cholesterol content …
METHODS: In a prospective case-cohort study within the Women's Health Study, TRL-C and sdLDL-C (mg/dl) were directly measured in base …
TRAIL therapy and prospective developments for cancer treatment.
Thapa B, Kc R, Uludağ H. Thapa B, et al. J Control Release. 2020 Oct 10;326:335-349. doi: 10.1016/j.jconrel.2020.07.013. Epub 2020 Jul 17. J Control Release. 2020. PMID: 32682900 Review.
However, recombinant human TRAIL protein (rhTRAIL) and TRAIL-R agonist monoclonal antibodies (mAb) failed to exert robust anticancer activities due to inherent and/or acquired resistance, poor pharmacokinetics and weak potencies for apoptosis induction. To get TRAIL back o …
However, recombinant human TRAIL protein (rhTRAIL) and TRAIL-R agonist monoclonal antibodies (mAb) failed to exert robust anticancer activit …
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggesi I, Rocchetti M. Simeoni M, et al. Cancer Res. 2004 Feb 1;64(3):1094-101. doi: 10.1158/0008-5472.can-03-2524. Cancer Res. 2004. PMID: 14871843
The parameters of the pharmacodynamic model are related to the growth characteristics of the tumor, to the drug potency, and to the kinetics of the tumor cell death. Therefore, such parameters can be used for ranking compounds based on their potency and for evaluati …
The parameters of the pharmacodynamic model are related to the growth characteristics of the tumor, to the drug potency, and to the k …
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.
McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. McTigue M, et al. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18281-9. doi: 10.1073/pnas.1207759109. Epub 2012 Sep 17. Proc Natl Acad Sci U S A. 2012. PMID: 22988103 Free PMC article.
The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clinical performance [Rini BI, et al. (2011) Lancet 378:193-1939]. To elucidate how fundamental drug potency-efficiency is achieved and impacts …
The first head-to-head randomized phase III comparative study between active VEGFR TKIs has confirmed significant differences in clinical pe …
Bench-to-Bedside Theranostics in Nuclear Medicine.
Jokar N, Assadi M, Yordanova A, Ahmadzadehfar H. Jokar N, et al. Curr Pharm Des. 2020;26(31):3804-3811. doi: 10.2174/1381612826666200218104313. Curr Pharm Des. 2020. PMID: 32067609 Review.
Theranostics is developing a strategy that can be used to implement accepted tools for individual molecular targeting, including diagnostics, and advances in genomic molecular knowledge, which has led to identifying theranostics biomaterials that have the potency to diagno …
Theranostics is developing a strategy that can be used to implement accepted tools for individual molecular targeting, including diagnostics …
Treating autoimmune disorders with venom-derived peptides.
Shen B, Cao Z, Li W, Sabatier JM, Wu Y. Shen B, et al. Expert Opin Biol Ther. 2017 Sep;17(9):1065-1075. doi: 10.1080/14712598.2017.1346606. Epub 2017 Jul 11. Expert Opin Biol Ther. 2017. PMID: 28695745 Review.
Consequently, Kv1.3 channel-inhibiting venom-derived peptides are a prospective resource for new drug discovery and clinical application. ...This review highlights the advances in screening and design of these peptides with diverse structures and potencies. It focus …
Consequently, Kv1.3 channel-inhibiting venom-derived peptides are a prospective resource for new drug discovery and clinical applicat …
Choosing appropriate pharmacotherapy for drug-resistant HIV.
Capetti A, Rizzardini G. Capetti A, et al. Expert Opin Pharmacother. 2019 Apr;20(6):667-678. doi: 10.1080/14656566.2019.1570131. Epub 2019 Jan 24. Expert Opin Pharmacother. 2019. PMID: 30676115 Review.
Despite the potency of current antiretrovirals, some patients continue to struggle with the management of the treatment of HIV due to drug resistance-associated mutations. ...They also consider the pharmacological aspects of antiretroviral therapy including the genetic bar …
Despite the potency of current antiretrovirals, some patients continue to struggle with the management of the treatment of HIV due to …
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.
Velikyan I, Eriksson O. Velikyan I, et al. Theranostics. 2020 Jan 1;10(1):437-461. doi: 10.7150/thno.38366. eCollection 2020. Theranostics. 2020. PMID: 31903131 Free PMC article. Review.
In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like pe …
In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review present …
Prospective Leads from Endophytic Fungi for Anti-Inflammatory Drug Discovery.
Pal PP, Shaik AB, Begum AS. Pal PP, et al. Planta Med. 2020 Sep;86(13-14):941-959. doi: 10.1055/a-1140-8388. Epub 2020 Apr 25. Planta Med. 2020. PMID: 32334437 Free article.
Further, the article gives a detailed insight into the compounds, their endophytic source, and anti-inflammatory target as well as potency. The contents of the article cover all the scientific reports published until Feb. 2019. ...
Further, the article gives a detailed insight into the compounds, their endophytic source, and anti-inflammatory target as well as potenc …
Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.
Zhang E, Ruth KJ, Buyyounouski MK, Price RA Jr, Uzzo RG, Sobczak ML, Pollack A, Wong JK, Chen DYT, Hallman MA, Greenberg RE, Watkins-Bruner D, Al-Saleem T, Horwitz EM. Zhang E, et al. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1074-1084. doi: 10.1016/j.ijrobp.2022.12.008. Epub 2022 Dec 23. Int J Radiat Oncol Biol Phys. 2023. PMID: 36566906 Free PMC article. Clinical Trial.
Erectile potency was assessed with components of the International Index of Erectile Function and phosphodiesterase type 5 inhibitor (PDE5) medication records. RESULTS: Sixty-two patients received ETS-IMRT, and 54 received s-IMRT; 1 patient did not receive radiation therap …
Erectile potency was assessed with components of the International Index of Erectile Function and phosphodiesterase type 5 inhibitor …
1,721 results